A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2013
At a glance
- Drugs Fenretinide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 12 May 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 07 Feb 2009 Actual patient numbers (37) added as reported by ClinicalTrials.gov.